全文获取类型
收费全文 | 877篇 |
免费 | 39篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 27篇 |
妇产科学 | 35篇 |
基础医学 | 117篇 |
口腔科学 | 6篇 |
临床医学 | 76篇 |
内科学 | 188篇 |
皮肤病学 | 68篇 |
神经病学 | 73篇 |
特种医学 | 41篇 |
外科学 | 72篇 |
综合类 | 14篇 |
一般理论 | 5篇 |
预防医学 | 45篇 |
眼科学 | 19篇 |
药学 | 78篇 |
中国医学 | 2篇 |
肿瘤学 | 52篇 |
出版年
2023年 | 7篇 |
2022年 | 10篇 |
2021年 | 17篇 |
2020年 | 8篇 |
2019年 | 12篇 |
2018年 | 20篇 |
2017年 | 13篇 |
2016年 | 21篇 |
2015年 | 23篇 |
2014年 | 37篇 |
2013年 | 52篇 |
2012年 | 42篇 |
2011年 | 55篇 |
2010年 | 41篇 |
2009年 | 24篇 |
2008年 | 52篇 |
2007年 | 44篇 |
2006年 | 58篇 |
2005年 | 63篇 |
2004年 | 44篇 |
2003年 | 40篇 |
2002年 | 43篇 |
2001年 | 6篇 |
2000年 | 9篇 |
1999年 | 13篇 |
1998年 | 13篇 |
1997年 | 6篇 |
1996年 | 4篇 |
1995年 | 5篇 |
1994年 | 9篇 |
1993年 | 5篇 |
1992年 | 7篇 |
1991年 | 10篇 |
1990年 | 11篇 |
1989年 | 15篇 |
1988年 | 11篇 |
1987年 | 4篇 |
1985年 | 11篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1981年 | 3篇 |
1979年 | 6篇 |
1977年 | 4篇 |
1976年 | 5篇 |
1975年 | 3篇 |
1974年 | 2篇 |
1973年 | 3篇 |
1971年 | 2篇 |
1967年 | 2篇 |
1965年 | 3篇 |
排序方式: 共有928条查询结果,搜索用时 0 毫秒
921.
Dr. Bela Blasszauer 《HEC forum》1991,3(5):277-283
Hungarian medical ethics committees were established at the end of the 1950s. They came into being on the Communist Party's initiative. They could hardly be called "interdisciplinary" since their membership was made up of high-ranking physicians and a few head nurses. Their main task was to counter the practice of "tipping." Medical ethics and "tipping" were practically synonymous. These committees did not confront or try to resolve ethical problems concerning such issues as patient rights, informed consent, refusal of treatment, human experimentation, abortion, etc. These committees - whether it is believable or not - belonged to the Physicians Health Workers Trade Union. They were under the guidance and supervision of this social organization. The public was excluded from their meetings, and the committees' duty was to follow the health laws which were supposed to have given excellent ethical guidance. Even in a textbook on medical ethics used at one of the medical universities, written by a psychiatrist, the health laws were presented and explained back and forth. Of the 88 pages only 23 dealt with morals in general and the Hippocratic tradition. The Hungarian National Health Service as well as its medical ethics committees are similar in many respects to the Soviet and Eastern European countries' health care system and ethics committees. Since radical changes have taken place in these so-called "former" communist countries, it can only be hoped that these committees will eventually develop into groups who will deal directly with the moral questions or medicine and health care. 相似文献
922.
Hugo Maia Jr Head of Research Kleber Pimentel Tânia M. Correia Silva Luíz A. R. Freitas Bela Zausner Célia Athayde 《Gynecological endocrinology》2013,29(4):219-224
Objectives.?To study the changes in aromatase, Ki-67 and cyclooxygenase-2 (COX-2) expression during the menstrual cycle in both endometrial polyps and normal endometria.Patients and methods.?Paraffin-embedded tissue samples from 118 premenopausal patients were submitted to immunohistochemistry for measurement of aromatase, COX-2 and Ki-67 expression. Fifty cases of endometrial polyps and 68 cases of disease-free endometrium were included.Results.?The presence of aromatase expression was significantly higher in endometrial polyps than in disease-free endometria. On the other hand, changes in COX-2 and Ki-67 expression followed a similar pattern during the menstrual cycle in both groups, expression peaking during the proliferative phase and falling during the late luteal phase.Conclusion.?A significantly higher proportion of endometrial polyps express aromatase compared with disease-free endometrium; however, no correlation was found between aromatase expression and changes in either Ki-67 or COX-2 expression during the menstrual cycle. 相似文献
923.
Rehnstrm Loi Ulrika Prata Ndola Grossman Amy Lavelanet Antonella Williams Natalie Ganatra Bela 《Reproductive health》2023,20(1):1-15
The World Health Organization (WHO) Labour Care Guide (LCG) is a paper-based labour monitoring tool designed to facilitate the implementation of WHO’s latest guidelines for effective, respectful care during labour and childbirth. Implementing the LCG into routine intrapartum care requires a strategy that improves healthcare provider practices during labour and childbirth. Such a strategy might optimize the use of Caesarean section (CS), along with potential benefits on the use of other obstetric interventions, maternal and perinatal health outcomes, and women’s experience of care. However, the effects of a strategy to implement the LCG have not been evaluated in a randomised trial. This study aims to: (1) develop and optimise a strategy for implementing the LCG (formative phase); and (2) To evaluate the implementation of the LCG strategy compared with usual care (trial phase). In the formative phase, we will co-design the LCG strategy with key stakeholders informed by facility assessments and provider surveys, which will be field tested in one hospital. The LCG strategy includes a LCG training program, ongoing supportive supervision from senior clinical staff, and audit and feedback using the Robson Classification. We will then conduct a stepped-wedge, cluster-randomized pilot trial in four public hospitals in India, to evaluate the effect of the LCG strategy intervention compared to usual care (simplified WHO partograph). The primary outcome is the CS rate in nulliparous women with singleton, term, cephalic pregnancies in spontaneous labour (Robson Group 1). Secondary outcomes include clinical and process of care outcomes, as well as women’s experience of care outcomes. We will also conduct a process evaluation during the trial, using standardized facility assessments, in-depth interviews and surveys with providers, audits of completed LCGs, labour ward observations and document reviews. An economic evaluation will consider implementation costs and cost-effectiveness. Findings of this trial will guide clinicians, administrators and policymakers on how to effectively implement the LCG, and what (if any) effects the LCG strategy has on process of care, health and experience outcomes. The trial findings will inform the rollout of LCG internationally. Trial registration: CTRI/2021/01/030695 (Protocol version 1.4, 25 April 2022). The new WHO Labour Care Guide (LCG) is an innovative partograph that emphasises women-centred, evidence-based care during labour and childbirth. Together with clinicians working at four hospitals in India, we will develop and test a strategy to implement the LCG into routine care in labour wards of these hospitals. We will use a randomised trial design where this LCG strategy is introduced sequentially in each of the four hospitals, in a random order. We will collect data on all women giving birth and their newborns during this period and analyse whether the LCG strategy has any effects on the use of Caesarean section, women’s and newborn’s health outcomes, and women’s experiences during labour and childbirth. While the trial is being conducted, we will also collect qualitative and quantitative data from doctors, nurses and midwives working in these hospitals, to understand their perspectives and experiences of using the LCG in their day-to-day work. In addition, we will collect economic data to understand how much the LCG strategy costs, and how much money it might save if it is effective. Through this study, our international collaboration will generate critical evidence and innovative tools to support implementation of the LCG in other countries. 相似文献
924.
David M. Fairlamb Bela Kelety Anke Bachert Anika Scholtissek Richard D. Jones Stephen C. Davis Robert S. Kirsner 《International wound journal》2023,20(6):2095-2104
A new recombinant proteolytic enzyme, isolated from maggot saliva, with fibrinolytic action has been investigated through a series of non-clinical toxicology and in-vitro/in-vivo pharmacology studies to explore its potential safety and efficacy as an enzymatic debridement agent for use in chronic wounds. Studies indicate that the enzyme has a good safety profile. When locally administered, it is not detrimental to wound healing, is non-sensitising and is rapidly inactivated in the systemic circulation. Adverse effects are limited, at very high concentrations, to transient erythema at the site of application. In-vitro testing indicates that the enzyme, whilst selective for fibrin, has additional proteolytic action against collagen and elastin, with enzymatic action for all three substrates being dose dependent. In-vivo, we used an established MRSA biofilm model, in which microbiological counts were used as a surrogate for debridement efficacy. Here, we showed that higher concentrations of the enzyme in a formulated proprietary gel, significantly reduced MRSA counts over a period of 2 to 14 days, and significantly improved the vascularity of the wound at 14 days. Together, these data support the potential for this maggot-derived proteolytic enzyme as a clinically effective debriding agent. 相似文献
925.
Samantha Spanos BPsych PhD Nehal Singh BPsych Bela I. Laginha BA/BSc MMSc Gaston Arnolda BSc MPH PhD David Wilkinson MBChB PhD FRACGP Andrea L. Smith BSc MPH PhD Anne E. Cust BA BSc MPH PhD Jeffrey Braithwaite BA DipLR MIR MBA PhD FIML FACHSM FAHMS FFPHRCP FAcSS Hon FRACMA Frances Rapport PhD MPhil BA Cert Ed FRSA 《The Australasian journal of dermatology》2023,64(2):177-193
Skin cancer is a growing global problem and a significant health and economic burden. Despite the practical necessity for skin cancer to be managed in primary care settings, little is known about how quality of care is or should be measured in this setting. This scoping review aimed to capture the breadth and range of contemporary evidence related to the measurement of quality in skin cancer management in primary care settings. Six databases were searched for relevant texts reporting on quality measurement in primary care skin cancer management. Data from 46 texts published since 2011 were extracted, and quality measures were catalogued according to the three domains of the Donabedian model of healthcare quality (structure, process and outcome). Quality measures within each domain were inductively analysed into 13 key emergent groups. These represented what were deemed to be the most relevant components of skin cancer management as related to structure, process or outcomes measurement. Four groups related to the structural elements of care provision (e.g. diagnostic tools and equipment), five related to the process of care delivery (e.g. diagnostic processes) and four related to the outcomes of care (e.g. poor treatment outcomes). A broad range of quality measures have been documented, based predominantly on articles using retrospective cohort designs; systematic reviews and randomised controlled trials were limited. 相似文献
926.
927.
928.
Mia Bierbaum Frances Rapport Gaston Arnolda Yvonne Tran Brona Nic Giolla Easpaig Kristiana Ludlow Robyn Clay-Williams Elizabeth Austin Bela Laginha Chi Yhun Lo Kate Churruca Lieke van Baar Karen Hutchinson Renuka Chittajallu Syeda Somyyah Owais Ruqaiya Nullwala Peter Hibbert Diana Fajardo Pulido Jeffrey Braithwaite 《Asia-Pacific Journal of Clinical Oncology》2023,19(6):618-644
Adherence to cancer treatment clinical practice guidelines (CPGs) varies enormously across Australia, despite being associated with improved patient outcomes. This systematic review aims to characterize adherence rates to active-cancer treatment CPGs in Australia and related factors to inform future implementation strategies. Five databases were systematically searched, abstracts were screened for eligibility, a full-text review and critical appraisal of eligible studies performed, and data extracted. A narrative synthesis of factors associated with adherence was conducted, and the median adherence rates within cancer streams calculated. A total of 21,031 abstracts were identified. After duplicates were removed, abstracts screened, and full texts reviewed, 20 studies focused on adherence to active-cancer treatment CPGs were included. Overall adherence rates ranged from 29% to 100%. Receipt of guideline recommended treatments was higher for patients who were younger (diffuse large B-cell lymphoma [DLBCL], colorectal, lung, and breast cancer); female (breast and lung cancer), and male (DLBCL and colorectal cancer); never smokers (DLBCL and lung cancer); non-Indigenous Australians (cervical and lung cancer); with less advanced stage disease (colorectal, lung, and cervical cancer), without comorbidities (DLBCL, colorectal, and lung cancer); with good-excellent Eastern Cooperative Oncology Group performance status (lung cancer); living in moderately accessible places (colon cancer); and; treated in metropolitan facilities (DLBLC, breast and colon cancer). This review characterized active-cancer treatment CPG adherence rates and associated factors in Australia. Future targeted CPG implementation strategies should account for these factors, to redress unwarranted variation particularly in vulnerable populations, and improve patient outcomes (Prospero number: CRD42020222962). 相似文献